Tominersen
- Generic Name
- Tominersen
- Drug Type
- Biotech
- CAS Number
- 1709886-74-7
- Unique Ingredient Identifier
- 7QI41X9QWC
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.
Phase 2
Active, not recruiting
- Conditions
- Huntington Disease
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 301
- Registration Number
- NCT05686551
- Locations
- ๐บ๐ธ
Uab Medicine, Birmingham, Alabama, United States
๐บ๐ธBarrow Neurological Institute, Phoenix, Arizona, United States
๐บ๐ธUniversity of California Davis Medical System, Sacramento, California, United States
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 899
- Registration Number
- NCT03761849
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐ต๐ฑKrakowska Akademia Neurologii Sp z o.o. Centrum Neurologii K, Krakow, Poland
๐บ๐ธUniversity of Pittsburgh, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath